Financial PerformanceProceeds from this transaction strengthen Idorsia’s balance sheet and will fund investment in accelerating the commercial trajectory of QUVIVIQ and advancing a risk-mitigated, science-driven pipeline.
Market ExpansionGlobal expansion of QUVIVIQ continues, as Simcere is in the process of introducing the product in China, opening an additional royalty stream for Idorsia.
Regulatory ApprovalsAprocitentan has achieved regulatory approval in both the U.S. and Europe, which could lead to a partnership and increased commercial traction.